Salvador
Martín Algarra
Consultor Médico
Publications (159) Salvador Martín Algarra publications
2024
-
Access to melanoma drugs in Spain: a cross-sectional survey
Clinical and Translational Oncology, Vol. 26, Núm. 10, pp. 2572-2583
-
Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis
Clinical and Translational Oncology
-
Thyroid dysfunction caused by immune checkpoint inhibitors improves cancer outcomes
Endocrine-related cancer, Vol. 31, Núm. 10
2023
-
Functional Engagement of the PD-1/PD-L1 Complex But Not PD-L1 Expression Is Highly Predictive of Patient Response to Immunotherapy in Non-Small-Cell Lung Cancer
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 14, pp. 2561-2570
-
SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry
Clinical and Translational Oncology, Vol. 25, Núm. 3, pp. 768-775
-
Variation in response rates to isolated limb perfusion in different soft-tissue tumour subtypes: an international multi-centre study
European Journal of Cancer, Vol. 190
2021
-
Diffuse dermal mucinosis secondary to colony-stimulating factor 1 receptor monoclonal antibody treatment: A novel and peculiar drug-induced diffuse cutaneous mucinosis
Journal of Dermatology, Vol. 48, Núm. 3, pp. 380-384
-
Erratum: Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma (Cancer Cell (2020) 38(4) (500–515.e3), (S1535610820304165), (10.1016/j.ccell.2020.08.005))
Cancer Cell
-
Evaluation of patient quality care in Spain in prevention of nausea and vomiting induced by chemotherapy
Journal of Healthcare Quality Research, Vol. 36, Núm. 3, pp. 142-149
-
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma
Journal of Clinical Oncology, Vol. 39, Núm. 24, pp. 2656-2666
-
Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 6, pp. 586-598
2020
-
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
Cancer Cell, Vol. 38, Núm. 4, pp. 500-515.e3
-
Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors
Science Translational Medicine, Vol. 12, Núm. 565
-
Predicting circulating biomarker response and its impact on the survival of advanced melanoma patients treated with adjuvant therapy
Scientific Reports, Vol. 10, Núm. 1
2019
-
A retrospective chart review study describing metastatic melanoma patients profile and treatment patterns in Spain
Clinical and Translational Oncology, Vol. 21, Núm. 12, pp. 1754-1762
-
Effectiveness of dabrafenib in the treatment of patients with braf v600-mutated metastatic melanoma in a named patient program
Melanoma Research, Vol. 29, Núm. 5, pp. 527-532
-
Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma
Oncologist, Vol. 24, Núm. 10, pp. 1375-1383
2018
-
Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types
Annals of Oncology, Vol. 29, Núm. 10, pp. 2121-2128
-
Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients
Annals of Oncology, Vol. 29, Núm. 5, pp. 1312-1319
-
Dermatología
Guía inmunotoxicidad: diagnóstico y manejo de los efectos secundarios asociados a inmunoterapia en oncología (EUNSA. Ediciones Universidad de Navarra, S.A.), pp. 36-51